H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Sangamo Biosciences (NASDAQ:SGMO) on Friday, setting a price target of $14, which is approximately 21.74% above the present share price of $11.5.
Chattopadhyay expects Sangamo Biosciences to post earnings per share (EPS) of -$0.37 for the third quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Sangamo Biosciences, with an average price target of $15.67.
The analysts price targets range from a high of $22 to a low of $11.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $13.08 million and a net profit of -$44.52 million. The company's market cap is $1.65 billion.
According to TipRanks.com, H.C. Wainwright analyst Debjit Chattopadhyay is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.4% and a 48.19% success rate.
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.